Dr Reddy’s Laboratories (RDY)
A major Indian pharmaceutical company, dual-listed in India and as a NYSE ADR.
RDY
Dr Reddy’s Laboratories · US · Data: Yahoo Finance, delayed
The thesis
Dr Reddy’s is a leading Indian drugmaker focused heavily on generics, including a large US generics business, which makes its NYSE ADR (RDY) a natural complement to its Indian listing. The US market is both a key revenue source and a key regulator via the FDA.
The cross-listing lets investors track the same company in rupees and dollars. For Indians the local share is the usual instrument; the ADR reflects global and especially US investor interest in Indian pharma.
How it makes money
Develops, manufactures and sells generic and branded medicines and active pharmaceutical ingredients, with significant sales in the US, India, Russia and other markets.
- + Large US generics franchise plus India branded business
- + Diversified geographic mix
- + R&D pipeline and complex generics
- + Cost-competitive Indian manufacturing
- - US generic price erosion
- - FDA inspection and compliance risk
- - Currency and pricing pressure
- - Patent-cliff and competition timing
- • New US product approvals and launches
- • FDA inspection outcomes for plants
- • Quarterly results and US pricing trends
- - Regulatory or quality issues at facilities
- - Generic price competition
- - Currency swings
- - Litigation and pricing scrutiny
How to buy RDY from India
Domestic investors typically buy the local Dr Reddy’s share on the NSE or BSE. The NYSE ADR (RDY) is buyable via a US-stocks account under the LRS for dollar exposure and reflects US investor interest in Indian pharma.
See routes, brokers & tax →The balanced view
An Indian pharma major whose US generics exposure makes the RDY ADR especially relevant. Local share for Indians; ADR as the US-facing mirror. Not a recommendation.
Other india adrs & cross-listings names
Educational and informational only. Downstox is not a SEBI-registered investment adviser. US securities involve currency, regulatory and market risk. Verify every figure and your own LRS/tax position before acting.